The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Icaritin Exacerbates Mitophagy and Synergizes with Doxorubicin to Induce Immunogenic Cell Death in Hepatocellular Carcinoma
Open accessAbstract
Abstract Hepatocellular carcinoma (HCC) resistant to both chemotherapy and immunotherapy is among the deadliest malignancies. Doxorubicin widely used in transarterial chemotherapy in HCC can induce immunogenic cell death (ICD), but the resulting immunogenicity is still weak. We aim to seek a strategy for improving the efficacy of ICD in HCC based on an immunoregulatory drug called icaritin. Icaritin induced mitophagy and apoptosis to provoke ICD both in mouse Hepa1–6 and human Huh7 HCC cells. A combination of icaritin and doxorubicin with a molar ratio of 1:2 played a synergistic role in ICD induction. The poly lactic-co-glycolic acid (PLGA)-polyethylene glycol (PEG)-aminoethyl anisamide (AEAA) nanoparticle (NP) targeted codelivery of icaritin and doxorubicin remodeled the immunosuppressive tumor microenvironment and triggered a robust immune memory response, which efficiently improved anti-HCC effect at an early stage in mouse HCC model. In addition, the combo PLGA-PEG-AEAA NP together with lenvatinib significantly prolonged survival time of mice at the advanced stage of HCC. Collectively, our findings reveal an anti-HCC mechanism of icaritin on mitophagy and provide an effective immune-based therapeutic strategy for HCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178
Coordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544
Immunogenic Cell Death in Cancer Therapy
Kroemer, G., Galluzzi, L., Kepp, O., & Zitvogel, L. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-100008 · Cited by 3,303
Autophagy in immunity and inflammation
Levine, B., Mizushima, N., & Virgin, H. W. (2011) · Nature · doi:10.1038/nature09782 · Cited by 3,289
Immunogenic cell death and DAMPs in cancer therapy
Krysko, D. V., Garg, A. D., Kaczmarek, A., Krysko, O., Agostinis, P., & Vandenabeele, P. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3380 · Cited by 3,223
Calreticulin exposure dictates the immunogenicity of cancer cell death
Obeid, M., Tesniere, A., Ghiringhelli, F., Fimia, G. M., Apetoh, L., Perfettini, J.-L., Castedo, M., Mignot, G., Panaretakis, T., Casares, N., et al. (2007) · Nature Medicine · doi:10.1038/nm1523 · Cited by 3,216
Llovet, J. M., Zucman-Rossi, J., Pikarsky, E., Sangro, B., Schwartz, M., Sherman, M., & Gores, G. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.18 · Cited by 2,531
Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death
Casares, N., Pequignot, M. O., Tesniere, A., Ghiringhelli, F., Roux, S., Chaput, N., Schmitt, E., Hamai, A., Hervas-Stubbs, S., Obeid, M., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050915 · Cited by 1,512
Autophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice
Michaud, M., Martins, I., Sukkurwala, A. Q., Adjemian, S., Ma, Y., Pellegatti, P., Shen, S., Kepp, O., Scoazec, M., Mignot, G., et al. (2011) · Science · doi:10.1126/science.1208347 · Cited by 1,377
PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect
Acharya, S., & Sahoo, S. K. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.10.008 · Cited by 1,112
Metabolic control of autophagy
Galluzzi, L., Pietrocola, F., Levine, B., & Kroemer, G. (2014) · Cell · doi:10.1016/j.cell.2014.11.006 · Cited by 855
Budhu, A., Forgues, M., Ye, Q.-H., Jia, H.-L., He, P., Zanetti, K. A., Kammula, U. S., Chen, Y., Qin, L.-X., Tang, Z.-Y., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.06.016 · Cited by 846
Exploiting non-covalent π interactions for catalyst design
Neel, A. J., Hilton, M. J., Sigman, M. S., & Toste, F. D. (2017) · Nature · doi:10.1038/nature21701 · Cited by 830
Autophagy balances inflammation in innate immunity
Deretic, V., & Levine, B. (2018) · Autophagy · doi:10.1080/15548627.2017.1402992 · Cited by 563
Xu, Y., Kim, C., Saylor, D. M., & Koo, D. (2017) · Journal of Biomedical Materials Research Part B: Applied Biomaterials · doi:10.1002/jbm.b.33648 · Cited by 424
Mitochondrial control of immunity: beyond ATP
Mehta, M. M., Weinberg, S. E., & Chandel, N. S. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.66 · Cited by 396
Human Tumor Cells Killed by Anthracyclines Induce a Tumor-Specific Immune Response
Fucikova, J., Kralikova, P., Fialova, A., Brtnicky, T., Rob, L., Bartunkova, J., & Špíšek, R. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0950 · Cited by 392
Song, W., Shen, L., Wang, Y., Liu, Q., Goodwin, T. J., Li, J., Dorosheva, O., Liu, T., Liu, R., & Huang, L. (2018) · Nature Communications · doi:10.1038/s41467-018-04605-x · Cited by 375
Self-citationChemical modulators of autophagy as biological probes and potential therapeutics
Fleming, A., Noda, T., Yoshimori, T., & Rubinsztein, D. C. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.500 · Cited by 349
A dual role of p53 in the control of autophagy
Tasdemir, E., Maiuri, M. C., Morselli, E., Criollo, A., D'Amelio, M., Djavaheri-Mergny, M., Cecconi, F., Tavernarakis, N., & Kroemer, G. (2008) · Autophagy · doi:10.4161/auto.6486 · Cited by 345
ROS-induced autophagy in cancer cells assists in evasion from determinants of immunogenic cell death
Garg, A. D., Dudek, A. M., Ferreira, G. B., Verfaillie, T., Vandenabeele, P., Krysko, D. V., Mathieu, C., & Agostinis, P. (2013) · Autophagy · doi:10.4161/auto.25399 · Cited by 305
Immune tolerance in liver disease
Crispe, I. N. (2014) · Hepatology · doi:10.1002/hep.27254 · Cited by 275
In vitro degradation of a novel poly(lactide-co-glycolide) 75/25 foam
Holy, C. E., Dang, S. M., Davies, J. E., & Shoichet, M. S. (1999) · Biomaterials · doi:10.1016/s0142-9612(98)00256-7 · Cited by 241
Danger signalling during cancer cell death: origins, plasticity and regulation
Garg, A. D., Martin, S., Golab, J., & Agostinis, P. (2014) · Cell Death & Differentiation · doi:10.1038/cdd.2013.48 · Cited by 226
Strange attractors: DAMPs and autophagy link tumor cell death and immunity
Hou, W., Zhang, Q., Yan, Z., Chen, R., Zeh III, H. J., Kang, R., Lotze, M. T., & Tang, D. (2013) · Cell Death & Disease · doi:10.1038/cddis.2013.493 · Cited by 193
Chen, Y., Chen, H.-N., Wang, K., Zhang, L., Huang, Z., Liu, J., Zhang, Z., Luo, M., Lei, Y., Peng, Y., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.09.022 · Cited by 189
Liu, Q., Chen, F., Hou, L., Shen, L., Zhang, X., Wang, D., & Huang, L. (2018) · ACS Nano · doi:10.1021/acsnano.8b01890 · Cited by 183
Self-citationGuo, S., Lin, C. M., Xu, Z., Miao, L., Wang, Y., & Huang, L. (2014) · ACS Nano · doi:10.1021/nn5010815 · Cited by 164
Self-citationAnti-Cancer Properties of the Naturally Occurring Aphrodisiacs: Icariin and Its Derivatives
Tan, H., Chan, K., Pusparajah, P., Saokaew, S., Duangjai, A., Lee, L., & Goh, B. H. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00191 · Cited by 160
Zappasodi, R., Pupa, S. M., Ghedini, G. C., Bongarzone, I., Magni, M., Cabras, A. D., Colombo, M. P., Carlo‐Stella, C., Gianni, A. M., & Nicola, M. D. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1825 · Cited by 150
Characterization of the Immune Microenvironment in Hepatocellular Carcinoma
Yarchoan, M. M., Xing, D., Luan, L., Xu, H., Sharma, R. B., Popović, A., Pawlik, T. M., Kim, A. K., Zhu, Q., Jaffee, E. M., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0950 · Cited by 149
Shen, L., Li, J., Liu, Q., Song, W., Zhang, X., Tiruthani, K., Hu, H., Das, M., Goodwin, T. J., Liu, R., et al. (2018) · ACS Nano · doi:10.1021/acsnano.8b00967 · Cited by 140
Self-citationStauffer, J. K., Scarzello, A. J., Jiang, Q., & Wiltrout, R. H. (2012) · Hepatology · doi:10.1002/hep.25674 · Cited by 138
Sigma receptors [σRs]: biology in normal and diseased states
Rousseaux, C. G., & Greene, S. F. (2015) · Journal of Receptors and Signal Transduction · doi:10.3109/10799893.2015.1015737 · Cited by 132
Relaxin gene delivery mitigates liver metastasis and synergizes with check point therapy
Hu, M., Wang, Y., Xu, L., An, S., Tang, Y., Zhou, X., Li, J., Liu, R., & Huang, L. (2019) · Nature Communications · doi:10.1038/s41467-019-10893-8 · Cited by 131
Self-citationFan, Y., Li, S., Ding, X., Yue, J., Jiang, J., Zhao, H., Hao, R., Qiu, W., Liu, K., Li, Y., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-5471-1 · Cited by 105
Wang, S.-F., Wu, M.-Y., Cai, C.-Z., Li, M., & Lu, J. (2016) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2016.10.069 · Cited by 95
Lymphocyte predominant Hodgkin’s disease: Pathology and clinical implication
Franklin, J. G., Tesch, H., Hansmann, M. L., & Diehl, V. (1998) · Annals of Oncology · doi:10.1093/annonc/9.suppl_5.s39 · Cited by 69
Li, J., Liu, P., Zhang, R., Cao, L., Qian, H., Liao, J., Xu, W., Wu, M., & Yin, Z.-F. (2011) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2011.06.030 · Cited by 50
Icaritin induces apoptotic and autophagic cell death in human glioblastoma cells.
Li, Z., Meng, X., & Jin, L. (2016) · PubMed · Cited by 30
Cited by
Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition)
Zhou, J., Sun, H., Wang, Z., Cong, W., Zeng, M., Zhou, W., Bie, P., Liu, L., Wen, T., Kuang, M., et al. (2023) · Liver Cancer · doi:10.1159/000530495 · Cited by 477
Zhai, J., Gu, X., Liu, Y., Hu, Y., Jiang, Y., & Zhang, Z. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1152934 · Cited by 131
Yu, Z., Guo, J., Liu, Y., Wang, M., Liu, Z., Gao, Y., & Huang, L. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-01205-8 · Cited by 114
Self-citation
Metadata
- Authors
- Yu, Z., Guo, J., Hu, M., Gao, Y., & Huang, L.
- Venue
- ACS Nano
- Publisher
- American Chemical Society (ACS)
- Published
- 2020-03-18
- Volume
- 14
- Issue
- 4
- Pages
- 4816-4828
- ISSN
- 1936-0851 (ISSN-L)
- 1936-086X
- OpenAlex
- W3011030655
- Cited by
- 433
- References
- 40
- FWCI
- 23.26
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.